Market Overview

OHR Pharmaceuticals Selling Off As Feuerstein Calls Phase II A Failure

40 Biggest Movers From Friday
Mid-Afternoon Market Update: Dow Climbs 170 Points; OHR Pharmaceutical Shares Slide

Shares of OHR Pharmaceuticals (NASDAQ: OHRP) are tumbling after Adam Feuerstein laid out the failure of the company’s phase II study.

As Feuerstein explained, the report looks positive; the title even totes “positive” results. This left many investors wondering why shares were selling off out of the open.

The fifth paragraph is the important one, which shows that OHR’s treatment did not outperform the placebo on the main focus of the study.

In addition, the so-called positive results are not statistically significant, Feuerstein points out.

Related: MKM Says Pandora Could Be Worth $115/Share In 5 Years

Shares of OHR Pharmaceuticals started selling off sharply when Feuerstein’s article was published, and are still dropping. The stock is at $9.87, over a 13 percent drop from Monday's close.

Latest Ratings for OHRP

Jan 2018Roth CapitalDowngradesBuyNeutral
Nov 2017Roth CapitalInitiates Coverage OnBuy
Oct 2016H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for OHRP
View the Latest Analyst Ratings

Posted-In: Adam Feuerstein CNBCAnalyst Color Analyst Ratings Media


Related Articles (OHRP)

View Comments and Join the Discussion!